DexCom, Inc. (DXCM)
After hours:
| Previous close | 134.30 |
| Open | 134.64 |
| Bid | 130.70 x 100 |
| Ask | 130.78 x 200 |
| Day's range | 129.18 - 135.06 |
| 52-week range | 74.75 - 142.00 |
| Volume | |
| Avg. volume | 3,051,636 |
| Market cap | 50.391B |
| Beta (5Y monthly) | 1.21 |
| PE ratio (TTM) | 100.55 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Dexcom Publishes Annual Sustainability Report
SAN DIEGO, April 03, 2024--DexCom, Inc. (NASDAQ:DXCM), the leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today released its annual Sustainability Report. This report provides updates on key corporate sustainability initiatives that are aligned with Dexcom’s core values and business strategy.
- Business Wire
Dexcom Schedules First Quarter 2024 Earnings Release and Conference Call for April 25, 2024 at 4:30 p.m. Eastern Time
SAN DIEGO, April 02, 2024--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2024 financial results after market close on Thursday, April 25, 2024. Management will hold a conference call to review the company's first quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be
- Business Wire
Stelo by Dexcom First Glucose Biosensor to be Cleared by FDA as Over-the-Counter
SAN DIEGO, March 05, 2024--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that the FDA has cleared Stelo by Dexcom – the first glucose biosensor that doesn’t require a prescription. There are approximately 25 million people in the U.S. living with Type 2 diabetes who do not use insulin and who can benefit from continuous glucose monitoring (CGM) technology. Today, Dexcom G7 is available for them with a prescripti
